Serum Progranulin Predicts High Activity of ANCA-Associated Vasculitis
By LabMedica International staff writers Posted on 18 Oct 2021 |

Image: Schematic diagram showing Anti-Neutrophil cytoplasmic antibody ANCA-induced ‘activation’ of neutrophils causing inflammation of the blood vessel wall (Photo courtesy of Addenbrooke’s Hospital)
Anti-Neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of chronic multisystem autoimmune diseases with substantial mortality and morbidity and frequent relapses. Progranulin is known to assume both pro-inflammatory roles and anti-inflammatory roles in the immune response.
The complexity of the disease condition and treatment-related adverse reactions as well as infections plays important roles in the poor outcomes. Unfortunately, the subjective symptoms and objective indicators are not fully parallel, and manifestations between disease activity and treatment-related adverse reactions are often similar.
Medical Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) selected 58 AAV patients with consecutive hospital identity numbers and were first diagnosed with AAV at their hospital between January 2019 and December 2020. Data regarding age, sex, AAV subtypes, ANCAs, and organ involvement were collected from patients during the visit for blood sample collection. The laboratory data, white blood cell and platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, glucose, blood urea nitrogen, serum creatinine, total protein, serum albumin, and complements 3 and 4 were collected. Serum progranulin concentration was quantified by ELISA kits (R&D Systems, Minneapolis, MN, USA).
The investigators reported that the median age of patients was 63.0 years and 19 were men. The median BVAS was 11.0, and the median serum progranulin level was 49.0 ng/mL. Serum progranulin was significantly correlated with Birmingham Vasculitis activity score (BVAS), Five-Factor Score (FFS), erythrocyte sedimentation rate, C-reactive protein level, SF-36 PCS, hemoglobin, and serum albumin. Severe AAV was arbitrarily defined as the highest tertile of BVAS (BVAS ≥16). When the cut-offs of serum progranulin were set as 55.2 ng/mL and 43.01 ng/mL for severe AAV, AAV patients with serum progranulin ≥55.2 and 43.01 ng/mL had significantly higher risks of severe AAV than those without (relative risk (RR) 4.167 and 4.524, respectively).
The authors concluded that progranulin might play an anti-inflammatory role in AAV pathogenesis and serum progranulin could be used as a predictive marker for high activity of AAV. The study was published on October 9, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Yonsei University College of Medicine
R&D Systems
The complexity of the disease condition and treatment-related adverse reactions as well as infections plays important roles in the poor outcomes. Unfortunately, the subjective symptoms and objective indicators are not fully parallel, and manifestations between disease activity and treatment-related adverse reactions are often similar.
Medical Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) selected 58 AAV patients with consecutive hospital identity numbers and were first diagnosed with AAV at their hospital between January 2019 and December 2020. Data regarding age, sex, AAV subtypes, ANCAs, and organ involvement were collected from patients during the visit for blood sample collection. The laboratory data, white blood cell and platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, glucose, blood urea nitrogen, serum creatinine, total protein, serum albumin, and complements 3 and 4 were collected. Serum progranulin concentration was quantified by ELISA kits (R&D Systems, Minneapolis, MN, USA).
The investigators reported that the median age of patients was 63.0 years and 19 were men. The median BVAS was 11.0, and the median serum progranulin level was 49.0 ng/mL. Serum progranulin was significantly correlated with Birmingham Vasculitis activity score (BVAS), Five-Factor Score (FFS), erythrocyte sedimentation rate, C-reactive protein level, SF-36 PCS, hemoglobin, and serum albumin. Severe AAV was arbitrarily defined as the highest tertile of BVAS (BVAS ≥16). When the cut-offs of serum progranulin were set as 55.2 ng/mL and 43.01 ng/mL for severe AAV, AAV patients with serum progranulin ≥55.2 and 43.01 ng/mL had significantly higher risks of severe AAV than those without (relative risk (RR) 4.167 and 4.524, respectively).
The authors concluded that progranulin might play an anti-inflammatory role in AAV pathogenesis and serum progranulin could be used as a predictive marker for high activity of AAV. The study was published on October 9, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Yonsei University College of Medicine
R&D Systems
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more